BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

PneumRx Inc. Raises $27 Million Round of Private Financing


3/5/2007 6:55:16 PM

MOUNTAIN VIEW, Calif., March 5 /PRNewswire/ -- PneumRx, Inc., a medical device company founded in 2004 to bring innovation and improvements to the diagnosis and treatment of lung cancer and Chronic Obstructive Pulmonary Disease (COPD, or emphysema), today announced the closing of a $27 million private placement of its Series B preferred stock. Adams Street Partners and Telegraph Hill Partners led the round, which also included Sage Venture Partners and Affiliates. They were joined by all of the existing investors, including Alta Partners, KBL Healthcare Ventures, and Spray Venture Partners.

PneumRx expects to use the Series B funds to complete clinical trials and prepare for commercialization of two major medical devices. PneumRx's PneuSeal(TM) product, a proprietary, highly adhesive sealant, is currently undergoing clinical trials in Germany to assess its safety and effectiveness for reducing pneumothorax complications in lung biopsy. On the COPD front, PneumRx has developed a unique Minimally Invasive Lung Volume Reduction Device that has demonstrated quantitative improvements in lung function and is expected to address a broader spectrum of emphysema patients. The device has shown an impressive ability to restore recoil in compromised lung. PneumRx plans to commence clinical trials on the Lung Volume Reduction Device later this year.

"We are thrilled to have completed our Series B round and look forward to working more closely with Adams Street Partners and Telegraph Hill Partners as their representatives join our board," said Erin McGurk, President and CEO of PneumRx, Inc. "We are extremely proud of the ambitious milestones we achieved with our Series A funding and are poised to use our latest investment round to build a self-sustaining company that addresses the tremendous pulmonary market opportunity."

About PneumRx, Inc.

Incorporated in 2004, PneumRx, Inc. is a rapidly growing medical device company focused on the development and commercialization of innovative products to diagnose and treat lung cancer and Chronic Obstructive Pulmonary Disease using minimally-invasive techniques.

PneumRx, Inc.

CONTACT: Kara Andersen of PneumRx, Inc., +1-650-625-8910, ext. 105

>>> Discuss This Story



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES